Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment: 48-week results from the MODERN study

Hans Jürgen Stellbrink, Eric L E Fevre, Andrew Carr, Michael S. Saag, Geoffrey Mukwaya, Silvia Nozza, Srinivas Rao Valluri, Manoli Vourvahis, Alex R. Rinehart, Lynn Mcfadyen, Carl Fichtenbaum, Andrew Clark, Charles Craig, Annie F. Fang, Jayvant Heera

Research output: Contribution to journalArticle

Abstract

OBJECTIVE:: To evaluate the efficacy of maraviroc plus darunavir/ritonavir, all once daily, for the treatment of antiretroviral-naive HIV-1–infected subjects. DESIGN:: MODERN was a multicenter, double-blind, non-inferiority, phase III study in HIV-1–infected, antiretroviral-naive adults with plasma HIV-1 RNA >1000?copies/mL and no evidence of reduced susceptibility to study drugs. METHODS:: At screening, participants were randomized 1:1 to undergo either genotypic or phenotypic tropism testing. Participants with CCR5-tropic HIV-1 were randomized 1:1 to receive maraviroc 150?mg once daily or tenofovir/emtricitabine once daily each with darunavir/ritonavir once daily for 96 weeks. The primary endpoint was the proportion of participants with HIV-1 RNA?

Original languageEnglish
JournalAIDS (London, England)
DOIs
Publication statusAccepted/In press - Feb 5 2016

Fingerprint

Tenofovir
Ritonavir
HIV-1
HIV
RNA
Tropism
Pharmaceutical Preparations
Darunavir
maraviroc
Emtricitabine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment : 48-week results from the MODERN study. / Stellbrink, Hans Jürgen; Fevre, Eric L E; Carr, Andrew; Saag, Michael S.; Mukwaya, Geoffrey; Nozza, Silvia; Valluri, Srinivas Rao; Vourvahis, Manoli; Rinehart, Alex R.; Mcfadyen, Lynn; Fichtenbaum, Carl; Clark, Andrew; Craig, Charles; Fang, Annie F.; Heera, Jayvant.

In: AIDS (London, England), 05.02.2016.

Research output: Contribution to journalArticle

Stellbrink, HJ, Fevre, ELE, Carr, A, Saag, MS, Mukwaya, G, Nozza, S, Valluri, SR, Vourvahis, M, Rinehart, AR, Mcfadyen, L, Fichtenbaum, C, Clark, A, Craig, C, Fang, AF & Heera, J 2016, 'Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment: 48-week results from the MODERN study', AIDS (London, England). https://doi.org/10.1097/QAD.0000000000001058
Stellbrink, Hans Jürgen ; Fevre, Eric L E ; Carr, Andrew ; Saag, Michael S. ; Mukwaya, Geoffrey ; Nozza, Silvia ; Valluri, Srinivas Rao ; Vourvahis, Manoli ; Rinehart, Alex R. ; Mcfadyen, Lynn ; Fichtenbaum, Carl ; Clark, Andrew ; Craig, Charles ; Fang, Annie F. ; Heera, Jayvant. / Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment : 48-week results from the MODERN study. In: AIDS (London, England). 2016.
@article{ceaa6d2ac086409089b835b686b7c8fe,
title = "Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment: 48-week results from the MODERN study",
abstract = "OBJECTIVE:: To evaluate the efficacy of maraviroc plus darunavir/ritonavir, all once daily, for the treatment of antiretroviral-naive HIV-1–infected subjects. DESIGN:: MODERN was a multicenter, double-blind, non-inferiority, phase III study in HIV-1–infected, antiretroviral-naive adults with plasma HIV-1 RNA >1000?copies/mL and no evidence of reduced susceptibility to study drugs. METHODS:: At screening, participants were randomized 1:1 to undergo either genotypic or phenotypic tropism testing. Participants with CCR5-tropic HIV-1 were randomized 1:1 to receive maraviroc 150?mg once daily or tenofovir/emtricitabine once daily each with darunavir/ritonavir once daily for 96 weeks. The primary endpoint was the proportion of participants with HIV-1 RNA?",
author = "Stellbrink, {Hans J{\"u}rgen} and Fevre, {Eric L E} and Andrew Carr and Saag, {Michael S.} and Geoffrey Mukwaya and Silvia Nozza and Valluri, {Srinivas Rao} and Manoli Vourvahis and Rinehart, {Alex R.} and Lynn Mcfadyen and Carl Fichtenbaum and Andrew Clark and Charles Craig and Fang, {Annie F.} and Jayvant Heera",
year = "2016",
month = "2",
day = "5",
doi = "10.1097/QAD.0000000000001058",
language = "English",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",

}

TY - JOUR

T1 - Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

T2 - 48-week results from the MODERN study

AU - Stellbrink, Hans Jürgen

AU - Fevre, Eric L E

AU - Carr, Andrew

AU - Saag, Michael S.

AU - Mukwaya, Geoffrey

AU - Nozza, Silvia

AU - Valluri, Srinivas Rao

AU - Vourvahis, Manoli

AU - Rinehart, Alex R.

AU - Mcfadyen, Lynn

AU - Fichtenbaum, Carl

AU - Clark, Andrew

AU - Craig, Charles

AU - Fang, Annie F.

AU - Heera, Jayvant

PY - 2016/2/5

Y1 - 2016/2/5

N2 - OBJECTIVE:: To evaluate the efficacy of maraviroc plus darunavir/ritonavir, all once daily, for the treatment of antiretroviral-naive HIV-1–infected subjects. DESIGN:: MODERN was a multicenter, double-blind, non-inferiority, phase III study in HIV-1–infected, antiretroviral-naive adults with plasma HIV-1 RNA >1000?copies/mL and no evidence of reduced susceptibility to study drugs. METHODS:: At screening, participants were randomized 1:1 to undergo either genotypic or phenotypic tropism testing. Participants with CCR5-tropic HIV-1 were randomized 1:1 to receive maraviroc 150?mg once daily or tenofovir/emtricitabine once daily each with darunavir/ritonavir once daily for 96 weeks. The primary endpoint was the proportion of participants with HIV-1 RNA?

AB - OBJECTIVE:: To evaluate the efficacy of maraviroc plus darunavir/ritonavir, all once daily, for the treatment of antiretroviral-naive HIV-1–infected subjects. DESIGN:: MODERN was a multicenter, double-blind, non-inferiority, phase III study in HIV-1–infected, antiretroviral-naive adults with plasma HIV-1 RNA >1000?copies/mL and no evidence of reduced susceptibility to study drugs. METHODS:: At screening, participants were randomized 1:1 to undergo either genotypic or phenotypic tropism testing. Participants with CCR5-tropic HIV-1 were randomized 1:1 to receive maraviroc 150?mg once daily or tenofovir/emtricitabine once daily each with darunavir/ritonavir once daily for 96 weeks. The primary endpoint was the proportion of participants with HIV-1 RNA?

UR - http://www.scopus.com/inward/record.url?scp=84957621037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957621037&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000001058

DO - 10.1097/QAD.0000000000001058

M3 - Article

AN - SCOPUS:84957621037

JO - AIDS

JF - AIDS

SN - 0269-9370

ER -